FDA Grants Breakthrough Therapy Designation for Acalabrutinib

August 1, 2017 – Today the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for acalabrutinib for the treatment of people with mantle cell lymphoma (MCL) who have received at least one prior therapy

While this news is for folks with mantle cell lymphoma, a cousin cancer to CLL, this is not an usual path to broader ultimate approval of a new medication.

Also, once a medication is approved, it can be used for any indication. though such “off label” insurance coverage can be a challenge

Overall, very good news

Read more: https://www.astrazeneca-us.com/media/press-releases/2017/acalabrutinib-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-mantle-cell-lymphoma-08012017.html

Ibrutinib Added to PBS Providing Reimbursement for CLL/SLL Patients In Australia
October 14, 2017

FDA Approval Brings First Gene Therapy to the United States
September 12, 2017

Blood Cancer Awareness Month and World Lymphoma Awareness Day
September 5, 2017

Venetoclax Approved For Use in Scotland
August 9, 2017

First Patient Dosed on a new BTK inhibitor for treating CLL
July 20, 2017

FDA Panel Recommends Approval for Gene-Altering Leukemia Treatment
July 12, 2017